Pancreatic Cancer

Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients
FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer
AIM ImmunoTech Shares Encouraging Data From Ampligen Study In Pancreatic Cancer
FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer
AIM ImmunoTech Shares Encouraging Data From Ampligen Study In Pancreatic Cancer
Amgen Posts Latest Batch of Lumakras Data In Pancreatic Cancer
PharmaCyte Updates Status Of Investigational New Drug Application For Pancreatic Cancer Candidate

Pancreatic Cancer Recent News

ImmunityBio's Shares Jump On Encouraging Data From Pancreatic Cancer Immunotherapy Trial
ImmunityBio Inc (NASDAQ: IBRX) has 
Why Did HCW Biologics Shares More Than Double Today?
Why Are Rafael Shares Plunging Today?
Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer
See Why RenovoRx Stock Is Shooting Higher On Tuesday
Lantern Pharma Secures FDA Orphan Drug Tag For Pancreatic Cancer Candidate
Why XOMA Stock Is Trading Higher Wednesday?
Novartis' TGFβ Targeted Antibody Secures FDA Orphan Drug Tag For Pancreatic Cancer
Lantern Pharma Shares Moves Higher On Encouraging Data From Pancreatic Cancer Candidate In Animal Models
Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer
Oncolytics Pelareorep/Pembrolizumab Combo Therapy Shows Anti-Cancer Activity In Pancreatic Cancer
AzurRx BioPharma Stock Gains On Positive MS1819-PERT Combo Data In Pancreatic Insufficiency
Galera Therapeutics Stock Surges After Its Lead Candidate Shows Median OS Of 20 Months In Pancreatic Cancer Study
XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic Cancer
Why Surface Oncology Shares Spiked 19% Today
Shares of Surface Oncology Inc. (NASDAQ: SURF), a clinical-stage biopharma company, gained more than 19% in the extended session on Tuesday.
AIM ImmunoTech Gets Orphan Drug Tag For Ampligen In Pancreatic Cancer
AIM ImmunoTech To Include New Patients In Netherlands Pancreatic Cancer Program
DSMB Recommends Hold On SBP-101 Administration In Early-Stage Metastatic Pancreatic Cancer Study, Shares Tank
NantKwest Reports Positive Interim Data In Pancreatic Cancer Trials, Stock Soars
Clinical-stage immunotherapy company Nantkwest Inc (NASDAQ: NK) 
Merrimack Plummets 30% After Pancreatic Cancer Drug Doesn't Meet Endpoints
EXCLUSIVE: VolitionRX CEO Talks Trial Updates, Time Until Market
New Drug Could Transform Pancreatic Cancer Treatment
13 Drug Companies Trying to Beat the Odds in Pancreatic Cancer

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved